key: cord-0751915-q481t5xg
authors: Thorne, Lucy G; Reuschl, Ann-Kathrin; Zuliani-Alvarez, Lorena; Whelan, Matthew V.X.; Noursadeghi, Mahdad; Jolly, Clare; Towers, Greg J
title: SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation
date: 2020-12-23
journal: bioRxiv
DOI: 10.1101/2020.12.23.424169
sha: b8a3f6f0f87e2865b1f4e3e2a70c6237493e8d02
doc_id: 751915
cord_uid: q481t5xg

SARS-CoV-2 infection causes broad-spectrum immunopathological disease, exacerbated by inflammatory co-morbidities. A better understanding of mechanisms underpinning virus-associated inflammation is required to develop effective therapeutics. Here we discover that SARS-CoV-2 replicates rapidly in lung epithelial cells despite triggering a robust innate immune response through activation of cytoplasmic RNA-ensors RIG-I and MDA5. The inflammatory mediators produced during epithelial cell infection can stimulate primary human macrophages to enhance cytokine production and drive cellular activation. Critically, this can be limited by abrogating RNA sensing, or by inhibiting downstream signalling pathways. SARS-CoV-2 further exacerbates the local inflammatory environment when macrophages or epithelial cells are primed with exogenous inflammatory stimuli. We propose that RNA sensing of SARS-CoV-2 in lung epithelium is a key driver of inflammation, the extent of which is influenced by the inflammatory state of the local environment, and that specific inhibition of innate immune pathways may beneficially mitigate inflammation-associated COVID-19. Highlights SARS-CoV-2 activates RNA sensors and consequent inflammatory responses in lung epithelial cells Epithelial RNA sensing responses drive pro-inflammatory macrophage activation Exogenous inflammatory stimuli exacerbate responses to SARS-CoV-2 in both eplithelial cells and macrophages Immunomodulators inhibit RNA sensing responses and consequent macrophage inflammation Graphical Abstract

SARS2CoV22% infection% causes% broad2spectrum% immunopathological% disease,% exacerbated% by% 18 inflammatory% co2morbidities.% A% better% understanding% of% mechanisms% underpinning% virus2 19 associated% inflammation% is% required% to% develop% effective% therapeutics.% Here% we% discover% that% 20

SARS2CoV22%replicates%rapidly%in%lung%epithelial%cells%despite%triggering%a%robust%innate%immune% 21 response% through% activation% of% cytoplasmic% RNA2sensors% RIG2I% and% MDA5.% The% inflammatory% 22 mediators%produced%during%epithelial%cell%infection%can%stimulate%primary%human%macrophages% 23 to% enhance% cytokine% production% and% drive% cellular% activation.% Critically,%this% can% be% limited% by% 24 abrogating%RNA%sensing,%or%by%inhibiting%downstream%signalling%pathways.%SARS2CoV22%further% 25 exacerbates% the% local% inflammatory% environment% when% macrophages% or% epithelial% cells% are% 26 primed%with%exogenous%inflammatory%stimuli.%We%propose%that%RNA%sensing%of%SARS2CoV22%in% 27 lung% epithelium% is% a% key% driver% of% inflammation,% the% extent% of% which% is% influenced% by% the% 28 inflammatory% state% of% the% local% environment,% and% that% specific% inhibition% of% innate% immune% 29 pathways%may%beneficially%mitigate%inflammation2associated%COVID219.%% 30 % 31

SARS2CoV22% has% caused% a% devastating% pandemic,% >74.8% million% confirmed% cases,% >1.6% million% 33 deaths% (https://covid19.who.int/,% 20 th % December% 2020)% and% a% worldwide% economic% crisis.% 34 Infection% causes% a% remarkably% wide,% but% poorly% understood,% disease% spectrum,% ranging% from% 35 asymptomatic% (Allen% et% al.,% 2020;Treibel% et% al.,% 2020)% to% severe% acute% respiratory% distress% 36 syndrome,%multi2organ%failure%and%death%(Docherty%et%al.,%2020;Zhou%et%al.,%2020).% 37 % 38

The%success%of%immunosuppressive%corticosteroid%dexamethasone%in%treating%COVID219%(Beigel% 39 et%al.,%2020)%suggests%the%importance%of%immunopathology%in%disease,%likely%driven%by%immune% 40 activation% in% infected% and% virus2exposed% cells.% Intracellular% innate% immune% responses% have% 41 evolved% to% detect% and% suppress% invading% pathogens,% but% inappropriate% responses% can% also% 42 contribute% to% disease% (Blanco2Melo% et% al.,% 2020;Park% and% Iwasaki,% 2020).% Pathogen% associated% 43 molecular% patterns% (PAMPs)% are% detected% by% pattern% recognition% receptors% (PRR),% including% 44 9 1 replication,% evidenced% by% lack% of% increase% in% viral% RNA% and% by% the% absence% of% N% positive% cells% 218 CoV22% infection% of% lung% epithelium% can% promote% immune% activation% of% inflammatory% 266 macrophages,%via%secretion%of%cytokines,%chemokines%and%virus%from%infected%cells,%and%that%this% 267 can% be% exacerbated% by% a% pre2existing% pro2inflammatory% state.% This% is% consistent% with% the% 268 hypothesis% that% chronic% inflammatory% states,% rather% than% enhanced% viral% replication,% drive% 269

We%found%that%SARS2CoV22%can%replicate%and%spread%effectively%in%lung%epithelial%Calu23%cells%over% 274 a%wide%range%of%inoculum%doses%despite%inducing%potent%IFN%responses%and%ISG%expression.%We% 275 1 propose% that% in% the% model% system% used% here,% innate% immune% activation% occurs% too% late% to% 276 suppress% replication% and% attribute% this% to% the% virus% deploying% innate% immune% evasion% and% 277 antagonism% strategies% early% in% infection.% Indeed,% coronaviruses% replicate% inside% membranous% 278 vesicles,% thought% to% protect% viral% RNA% species% from% cytoplasmic% sensing,% and% have% complex% 279 capacity%to%antagonise%innate%immunity,%including%inhibition%of%MDA5%activation%%(Liu%et%al.,%2020)% 280 and% preventing% nuclear% entry% of% inflammatory% transcription% factors% (Totura% and% Baric,% 281 2012;Banerjee%et%al.,%2020;Miorin%et%al.,%2020;Park%and%Iwasaki,%2020;Yuen%et%al.,%2020).%Indeed,% 282 it%is%possible%that%the%innate%immune%response%and%the%secreted%signals%produced%by%infected% 283 cells% are% dysregulated% by% viral% manipulation,% and% that% this% imbalanced% response% may% also% 284 contribute%to%disease%when%occurring%during%underlying%inflammatory%pathology%(Blanco2Melo%et% 285 al.,%2020;Giamarellos2Bourboulis%et%al.,%2020;Lucas%et%al.,%2020 

Calu23% cells% were% transfected% with% 40% pmol% of% siRNA% SMART% pool% against% RIG2I% (L20125112002 419 0005),% MDA5% (L201304120020005),% MAVS% (L202423720020005)% or% non2targeting% control% (D2 420 

Calu23%cells%were%pre2treated%with%Remdesivir% ( 

For% detection% of% ACE2% expression,% whole% cell% protein% lysates% were% separated% by% SDS2PAGE,% 482 transferred%onto%nitrocellulose%and%blocked%in%PBS%with%0.05%%Tween%20%and%5%%skimmed%milk.% 483

Membranes%were%probed%with%polyclonal%goat%anti2human%ACE2%(1:500,%AF933,%R&D%Biosystems)% 484 or% rabbit% anti2human% beat2Actin% (1:2500,% 6L12,% Sigma)% followed% by% donkey% anti2goat% IRdye% 485 680CW% or% goat% anti2rabbit% IRdye% 800CW% (Abcam),% respectively.% Blots% were% Imaged% using% an% 486 Odyssey%Infrared%Imager%(LI2COR%Biosciences)%and%analysed%with%Image%Studio%Lite%software.% 487 % 488

For%imaging%analysis,%Calu23%or%Caco22%cells%were%seeded%and%infected%with%SARS2CoV22%in%Optical% 490 962well%plates%(CellCarrier%Ultra,%PerkinElmer)%and%cells%were%fixed%with%4%%PFA%at%the%indicated% 491 timepoints.% Permeabilisation% was% carried% out% with% 0.1%% TRITON2X100% (Sigma)% in% PBS% for% 15% 492 minutes.% A% blocking% step% was% carried% out% for% 1h% at% room% temperature% with% 10%% goat% 493 serum/1%BSA%in%PBS.%Nucleocapsid%(N)%proten%%detection%was%performed%by%primary%incubation% 494 with%human%anti2N%antibody%(Cr3009,%1ug/ml)%for%18h,%and%washed%thoroughly%in%PBS.%Where% 495 appropriate,%N2protein%staining%was%followed%by%incubation%with%rabbit%anti2NFkB%(p65)%(sc2372,% 496 Santa%Cruz)%or%rabbit%anti2IRF3%(sc29082,%Santa%Cruz)%for%1%h.%Primary%antibodies%were%detected%by% 497 labelling% with% with% secondary% anti2human% AlexaFluor488% and% anti2rabbit% AlexaFluor546% 498 conjugates%(Jackson%Immuno%Research)%for%1h.%For%RNA%fluorescent%in#situ%hybridization)(FISH),% 499 cells% were% immunofluorescently% labelled% for% viral% N2protein% (detected% with% AlexaFluor488% or% 500

AlexaFluor546%conjugates)%followed%by%RNA%visualisation%using%the%ViewRNA%Cell%Plus%Kit%(Thermo% 501 Fisher).%The%ViewRNA%probes%implemented%targeted%ILA6%(VA4219075,%AlexaFluor488),%IFIT1%(VA42 502 18833,%AlexaFluor488)%and%GAPDH%(VA1210119,%AlexaFluor546).%All%cells%were%then%labelled%with% 503 HCS% CellMask% DeepRed% (H32721,% Thermo% Fisher)% and% Hoechst33342% (H3570,% Thermo% Fisher).% 504 Images% were% acquired% using% the% WiScan®% Hermes% High2Content% Imaging% System% (IDEA% Bio2 505 medical,%Rehovot,%Israel)%at%magnification%10X/0.4NA%or%40X/0.75NA.%Four%channel%automated% 506 acquisition% was% carried% out% sequentially% (DAPI/TRITC,% GFP/Cy5).% For% 10X% magnification% 100%% 507 20 1 density/100%% well% area% was% acquired,% resulting% in% 64% FOV/well.% For% 40X% magnification,% 35%% 508 density/%30%%well%area%was%acquired%resulting%in%102%FOV/well.%% 509 % 510

NF2!B,%IRF3,%IL6%and%GAPDH%raw%image%channels%were%pre2processed%using%a%batch%rolling%ball% 512 background% correction% in% FIJI% imagej% software% package% (Schindelin% et% al.,% 2012)% prior% to% 513 quantification.% Automated% image% analysis% was% carried% out% using% the% 'Athena'% HCS% analysis% 514 software%package%(IDEA%Bio2medical%IDEA%Bio2medical,%Rehovot,%Israel).%For%quantification%of%the% 515 percentage% of% nucleocapsid% positive% cells% within% the% population,% the% 'Intracellular% Granules'% 516 module%was%utilised.%Nuclei%were%segmented%using%Hoechst33342%signal.%Cell%boundaries%were% 517 determined%by%segmentation%of%CellMask%signal.%Infected%cells%were%determined%by%thresholding% 518 intracellular%N%protein%signal%(Intracellular%granules).%For%all%analysis,%the%N%protein%signal%intensity% 519 was% thresholded% against% the% mock% infected% wells% to% ensure% no% false% segmentation% of% N% +ve% 520 objects.% Nuclear% accumulation% of% NF2!B% or% IRF3% was% carried% out% using% the% 'Intranuclear% Foci'% 521 

Statistical%analysis%was%performed%using%GraphPad%Prism.%As%indicated,%normally%distributed%data% 533 was% analysed% for% statistical% significance% by% t2% tests% (when% comparing% two% groups)% or% one2way% 534 ANOVA% with% Bonferroni% or% Dunnett's% post2test% (when% comparing% more% than% two% groups).% 535

Wilcoxon%ranked%paired%non2parametric%tests%were%performed%for%primary%macrophage%data%that% 536 1 was% not% normally% distributed.% For% imaging% analysis,% where% appropriate,% integrated% intensities% 537 were% normalised% to% the% mean% intensity% of% the% mock% infected% population% for% that% respective% 538 Allen,%W.E.,%Altae2Tran,%H.,%Briggs,%J.,%Jin,%X.,%Mcgee,%G.,%Shi,%A.,%Raghavan,%R.,%Kamariza,%M.,% 553

Nova,%N.,%Pereta,%A.,%Danford,%C.,%Kamel,%A.,%Gothe,%P.,%Milam,%E.,%Aurambault,%J.,%Primke,% 554

T.,%Li,%W.,%Inkenbrandt,%J.,%Huynh,%T.,%Chen,%E.,%Lee,%C.,%Croatto,%M.,%Bentley,%H.,%Lu,%W.,% 555

Murray,%R.,%Travassos,%M.,%Coull,%B.A.,%Openshaw,%J.,%Greene,%C.S.,%Shalem,%O.,%King,%G.,% 556

Probasco,%R.,%Cheng,%D.R.,%Silbermann,%B.,%Zhang,%F.,%and%Lin,%X.%(2020 Philippot,%Q.,%Rosain,%J.,%Béziat,%V.,%Manry,%J.,%Shaw,%E.,%Haljasmägi,%L.,%Peterson,%P.,% 569

Lorenzo,%L.,%Bizien,%L.,%Trouillet2Assant,%S.,%Dobbs,%K.,%De%Jesus,%A.A.,%Belot,%A.,%Kallaste,% 570

A.,%Catherinot,%E.,%Tandjaoui2Lambiotte,%Y.,%Le%Pen,%J.,%Kerner,%G.,%Bigio,%B.,%Seeleuthner,% 571 1 Y.,%Yang,%R.,%Bolze,%A.,%Spaan,%A.N.,%Delmonte,%O.M.,%Abers,%M.S.,%Aiuti,%A.,%Casari,%G.,% 572

Lampasona,%V.,%Piemonti,%L.,%Ciceri,%F.,%Bilguvar,%K.,%Lifton,%R.P.,%Vasse,%M.,%Smadja,%D.M.,% 573

Migaud,%M.,%Hadjadj,%J.,%Terrier,%B.,%Duffy,%D.,%Quintana2Murci,%L.,%Van%De%Beek,%D.,% 574

Roussel,%L.,%Vinh,%D.C.,%Tangye,%S.G.,%Haerynck,%F.,%Dalmau,%D.,%Martinez2Picado,%J.,% 575

Brodin,%P.,%Nussenzweig,%M.C.,%Boisson2Dupuis,%S.,%Rodríguez2Gallego,%C.,%Vogt,%G.,% 576

Mogensen,%T.H.,%Oler,%A.J.,%Gu,%J.,%Burbelo,%P.D.,%Cohen,%J.I.,%Biondi,%A.,%Bettini,%L.R.,% 577 D'angio,%M.,%Bonfanti,%P.,%Rossignol,%P.,%Mayaux,%J.,%Rieux2Laucat,%F.,%Husebye,%E.S.,%Fusco,% 578 F.,%Ursini,%M.V.,%Imberti,%L.,%Sottini,%A.,%Paghera,%S.,%Quiros2Roldan,%E.,%Rossi,%C.,% 579

Castagnoli,%R.,%Montagna,%D.,%Licari,%A.,%Marseglia,%G.L.,%Duval,%X.,%Ghosn,%J.,%Tsang,%J.S.,% 580

Goldbach2Mansky Blanco2Melo,%D.,%Nilsson2Payant,%B.E.,%Liu,%W.C.,%Uhl,%S.,%Hoagland,%D.,%Møller,%R.,%Jordan,%T.X.,% 593

Oishi,%K.,%Panis,%M.,%Sachs,%D.,%Wang,%T.T.,%Schwartz,%R.E.,%Lim,%J.K.,%Albrecht,%R.A.,%and% 594

Tenoever,%B.R.%(2020).%Imbalanced%Host%Response%to%SARS2CoV22%Drives%Development%of% 

% 616 and%Eils

%Remdesivir:%A%Review%of%Its%Discovery%and%Development%Leading%to%Emergency% 637 Use%Authorization%for%Treatment%of%COVID219.%ACS#Cent#Sci%6,%6722683.% 638 Giamarellos2Bourboulis

% 716 SARS2coronavirus22%replication%in%Vero%E6%cells:%replication%kinetics,%rapid%adaptation% 717 and%cytopathology.%J#Gen#Virol%101,%9252940.%

%Murine%coronavirus%mouse%hepatitis%virus% 767 is%recognized%by%MDA5%and%induces%type%I%interferon%in%brain%macrophages/microglia.%J# 768 Virol%82

%SARS%coronavirus%pathogenesis:%host%innate%immune% 789 responses%and%viral%antagonism%of%interferon.%Curr#Opin#Virol%2,%2642275.%

%Bats,%civets%and%the%emergence%of%SARS.%Curr#Top#Microbiol# 794 Immunol%315

Structural%basis%for%dsRNA%recognition,%filament%formation,%and%antiviral%signal%activation% 805 by%MDA5.%Cell%152,%2762289.%

Measurements of replication and innate immune induction in Calu43 lung epithelial cells infected with SARS4CoV42 at MOIs 0.08, 0.4 and 2 TCID50 VERO /cell. Means shown +/4 SEM, n=2. (A) Replication of SARS4CoV42 genomic and subgenomic E RNAs (qRT4PCR). (B) Quantification of N staining from cells in (A) by flow cytometry. Mean percentage of N4positive of all

All data from cells in (A) at MOI 0.4 TCID50 VERO /cell. Mean +/4 SEM, n=2. (I,L) SARS4CoV4 2 infection (MOIs 0.04 (closed symbols) and 0.0004 (open symbols) TCID50 VERO /cell) in Calu43 cells with addition of 10ng/ml IFNβ before or after infection at time points shown, measured by (I) E RNA copies (J) N positive cells, (L) released virus (TCID50 VERO /cell) all measured at 24 hpi

A,D) Measurement of (A) viral genomic and subgenomic E RNA at 24 hpi, (B) fold induction of CXCL10 from (A), (C) IFIT2 and (D) ILF6 mRNA (qRTFPCR) from (A) after Remdesivir treatment (0.125F5 μM) of SARSFCoVF2 infected CaluF3 cells (MOI 0.04 TCID50/cell) with Remdesivir added 2h prior to infection. Mean +/F SEM, n=3. (E,H) Measurement of (E) viral genomic and subgenomic E RNA (F) fold induction of CXCL10

TCID50VERO/cell) with Remdesivir treatment (5μM) prior to, at the time of, or 8 h postFinfection. Mean +/F SEM, n=3, One way ANOVA with Dunnett's multiple comparisons test to compare to untreated infected condition

Nuclei (DAPI, blue). (J) RNAi mediated depletion of MAVS, RIGFI or MDAF5, reduced their expression levels as compared to siControl (siCtrl) Mean +/F SEM. TwoFWay ANOVA with Sidak's multiple comparisons test, **** (p<0.0001). (K,N) Fold induction of (K) CXCL10, (L) IFIT2, (M) ILF6 or (N) IFNβ in SARSFCoVF2 infected CaluF3 cells (MOI 0.04 TCID50/cell) 24 hpi. Mean +/F SEM, n=3, and compared to siCtrl for each gene by One Way ANOVA with Dunnett's multiple comparisons test, ** (p<0.01), *** (p<0.001), **** (p<0.0001), n.s. : non significant. (O) Live/dead stain counts for nonFadherent cells, recovered at 48 hpi from supernatants of SARSFCoVF2 infected CaluF3 cells

Figure 6. Pre*existing immune activation exacerbates SARS*CoV*2*dependent inflammation. (A) Schematic of experimental design

MDM were primed with 100ng/ml LPS for 2h before exposure to SARSCCoVC2 (MOI 0.02 TCID50VERO/cell). (B) Expression of genomic and subgenomic viral E RNA at 48 h post exposure in indicated conditions

Schematic of experimental design. MDM were exposed to SARSCCoVC2 (MOI 0.02 TCID50VERO/cell) for 48 h and subsequently stimulated with 100ng/ml LPS for 24 h. (J) Expression of genomic and subgenomic viral E RNA 72 h postCexposure in indicated conditions. (K*L) Host gene expression of (K) CCL5, (L) ISG56), IFIT2 (M), (N) ILC6 and (O) ILC1!. (P) ILC1! secretion was detected in culture supernatants at 48 hpi by ELISA. Gene expression is shown as fold induction over untreated controls. Data from 8C13 independent donors is shown. Groups were compared as indicated by Wilcoxon matchedCpairs signed rank test, *

Fold induction over untreated mock infection is shown, n=3. (U) NonCadherent cells were collected at 48h post infection and live/dead stained. Cells were acquired by flowcytometry and cell counts determined by timeCgating. For statistical comparison, total cell numbers were compared. (V) Viral release into culture supernatants at 24 h was measured by TCID50 on VeroE6 cells. (Q*V) Mock and SARSCCoVC2 infected conditions were compared with or without IL1bC treatment, respectively